Back to top
more

Celldex Therapeutics (CLDX)

(Delayed Data from NSDQ)

$21.80 USD

21.80
790,306

-0.39 (-1.76%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $21.79 -0.01 (-0.05%) 7:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Can UnitedHealth (UNH) Q4 Earnings Navigate Through High Costs?

by Zacks Equity Research

UnitedHealth's (UNH) fourth-quarter results are likely to reflect growth in domestic commercial customers and premium levels.

Zacks Equity Research

Mirati (MRTX) Up 1.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Celldex (CLDX) delivered earnings and revenue surprises of 0% and 60%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Celldex Therapeutics (CLDX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Celldex (CLDX) delivered earnings and revenue surprises of 1.59% and 157.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Celldex (CLDX): Can Its 7.1% Jump Turn into More Strength?

by Zacks Equity Research

Celldex (CLDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Celldex (CLDX) delivered earnings and revenue surprises of 0% and 62.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Merus N.V. (MRUS) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Merus N.V. (MRUS) delivered earnings and revenue surprises of 11.67% and 38.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Myriad Genetics (MYGN) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Myriad (MYGN) delivered earnings and revenue surprises of -375% and 9.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Celldex Therapeutics (CLDX) Q3 Earnings Expected to Decline

by Zacks Equity Research

Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Celldex Therapeutics (CLDX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Celldex (CLDX) delivered earnings and revenue surprises of -34.88% and 53.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

BioMarin (BMRN) delivered earnings and revenue surprises of 37.21% and 3.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Apellis' (APLS) Geographic Atrophy NDA Gets Priority Review

by Zacks Equity Research

The FDA accepts Apellis' (APLS) NDA for pegcetacoplan under a priority review for treating geographic atrophy secondary to age-related macular degeneration. A decision is due on Nov 26, 2022.

Zacks Equity Research

Wall Street Analysts See a 169% Upside in Celldex (CLDX): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Celldex (CLDX) points to a 169.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Celldex (CLDX) Surges 9%: Is This an Indication of Further Gains?

by Zacks Equity Research

Celldex (CLDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Celldex (CLDX) Down on Interim Data From Phase Ib Study in CSU

by Zacks Equity Research

Celldex (CLDX) posts interim data from the phase Ib study evaluating barzolvolimab in patients with moderate to severe chronic spontaneous urticaria. Shares down.

Zacks Equity Research

Celldex (CLDX) Initiates Phase II Chronic Skin Disorder Study

by Zacks Equity Research

Celldex (CLDX) initiates dosing in a mid-stage study designed to evaluate its antibody candidate, barzolvolimab, for treating patients with chronic spontaneous urticaria.

Zacks Equity Research

Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Celldex (CLDX) delivered earnings and revenue surprises of -6.52% and 76.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of 0% and 2.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is the Options Market Predicting a Spike in Celldex (CLDX) Stock?

by Zacks Equity Research

Investors need to pay close attention to Celldex (CLDX) stock based on the movements in the options market lately.

Zacks Equity Research

Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Celldex (CLDX) delivered earnings and revenue surprises of -11.43% and -91.02%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Celldex Therapeutics (CLDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Celldex (CLDX) Initiates Subcutaneous Skin Disorder Drug Study

by Zacks Equity Research

Celldex (CLDX) is developing subcutaneous as well as intravenous formulations of its antibody candidate, CDX-0159 as a potential treatment of several skin disorders.

Zacks Equity Research

Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Celldex (CLDX) delivered earnings and revenue surprises of 15.00% and 207.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Celldex Therapeutics (CLDX) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.